LivaNova PLC $LIVN Stake Boosted by Vanguard Group Inc.

Key Points

• Vanguard Group Inc. has increased its stake in LivaNova PLC by 13.5% during Q1, owning a total of 2,666,880 shares valued at approximately $104.8 million.
• LivaNova's recent earnings report showed an EPS of $1.05, surpassing analysts' expectations, with revenue growth of 10.6% year-over-year.
• Several analysts have upgraded their ratings for LivaNova, with average price targets now approaching $59.71 per share, indicating positive market sentiment.

Vanguard Group Inc. boosted its stake in LivaNova PLC (NASDAQ:LIVN - Free Report) by 13.5% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,666,880 shares of the company's stock after buying an additional 316,993 shares during the quarter. Vanguard Group Inc. owned approximately 4.89% of LivaNova worth $104,755,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Envestnet Asset Management Inc. raised its position in shares of LivaNova by 15.4% in the fourth quarter. Envestnet Asset Management Inc. now owns 43,932 shares of the company's stock valued at $2,034,000 after buying an additional 5,850 shares during the last quarter. Russell Investments Group Ltd. grew its stake in LivaNova by 17.1% in the 4th quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company's stock worth $70,000 after acquiring an additional 219 shares during the period. Invesco Ltd. raised its holdings in LivaNova by 0.6% in the 4th quarter. Invesco Ltd. now owns 111,374 shares of the company's stock valued at $5,158,000 after acquiring an additional 667 shares during the last quarter. Mariner LLC raised its holdings in LivaNova by 8.4% in the 4th quarter. Mariner LLC now owns 5,741 shares of the company's stock valued at $266,000 after acquiring an additional 446 shares during the last quarter. Finally, Walleye Capital LLC purchased a new position in shares of LivaNova during the 4th quarter worth $230,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

LivaNova Stock Down 1.5%

Shares of LIVN stock traded down $0.84 on Thursday, hitting $55.65. The stock had a trading volume of 33,170 shares, compared to its average volume of 704,011. The stock's 50 day moving average is $47.11 and its 200-day moving average is $43.24. The firm has a market capitalization of $3.04 billion, a price-to-earnings ratio of -14.27 and a beta of 0.92. LivaNova PLC has a 52-week low of $32.48 and a 52-week high of $57.35. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.09 and a current ratio of 1.29.

LivaNova (NASDAQ:LIVN - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $1.05 EPS for the quarter, topping analysts' consensus estimates of $0.84 by $0.21. The firm had revenue of $352.50 million for the quarter, compared to analyst estimates of $332.20 million. LivaNova had a negative net margin of 16.13% and a positive return on equity of 14.57%. The firm's revenue was up 10.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.93 EPS. As a group, research analysts expect that LivaNova PLC will post 2.85 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on LIVN. Barclays lifted their price objective on LivaNova from $55.00 to $58.00 and gave the company an "equal weight" rating in a research report on Thursday, August 21st. Needham & Company LLC reissued a "buy" rating and issued a $64.00 price target on shares of LivaNova in a research note on Tuesday, May 13th. Wall Street Zen upgraded LivaNova from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 9th. Robert W. Baird increased their price objective on shares of LivaNova from $55.00 to $61.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. Finally, Wolfe Research raised shares of LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 target price on the stock in a research report on Tuesday, May 20th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, LivaNova currently has an average rating of "Buy" and an average price target of $59.71.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.